Nuclea Biotechnologies, LLC is a translational medicine and genomics company dedicated to the identification of gene and protein biomarkers that are associated with specific disease states. Nuclea has developed a novel technology platform that greatly improves the efficiency of genomic research. The company’s primary focus is in the area of molecular oncology and pathology, but it has the capability of applying its technology to other diseases.

Nuclea’s extensive libraries of genetic, molecular and clinical outcomes data together with its bioinformatics capabilities enable it to rapidly and efficiently identify the most promising paths for diagnosing and treating oncological diseases.

TECHNOLOGY HIGHLIGHTS

• Therapeutic Development Program
• Gene Signatures
• Biorepositories and Clinical Data
• Array Based Technologies
• Kinase Antibodies